OBJECTIVE: To review the disease course in patients with steroid sensitive nephrotic syndrome (SSNS) and the factors that determine outcome DESIGN: Retrospective, analytical SETTING: Pediatric Nephrology Clinic at referral center in North India PARTICIPANTS/PATIENTS: All patients with SSNS evaluated between 1990 and 2005 INTERVENTION: None MAIN OUTCOME MEASURES: Disease course, in patients with at least 1-yr follow up, was categorized as none or infrequent relapses (IFR), frequent relapses or steroid dependence (FR), and late resistance. Details on complications and therapy with alternative agents were recorded. RESULTS: Records of 2603 patients (74.8% boys) were reviewed. The mean age at onset of illness and at evaluation was 49.7±34.6 and 67.5±37.9 months respectively. The disease course at 1-yr (n=1071) was categorized as IFR in 37.4%, FR in 56.8% and late resistance in 5.9%. During follow up, 224 patients had 249 episodes of serious infections. Alternative medications for frequent relapses (n=501; 46.8%) were chiefly cyclophosphamide and levamisole. Compared to IFR, patients with FR were younger (54.9±36.0 vs. 43.3±31.4 months), fewer had received adequate (=8 weeks) initial treatment (86.8% vs. 81.7%) and had shorter initial remission (7.5±8.6 vs. 3.1±4.8 months) (all P<0.001). At follow up of 56.0±42.6 months, 77.3% patients were in remission or had IFR, and 17.3% had FR. CONCLUSIONS: A high proportion of patients with SSNS show frequent relapses, risk factors for which were an early age at onset, inadequate initial therapy and an early relapse.
OBJECTIVE: To review the disease course in patients with steroid sensitive nephrotic syndrome (SSNS) and the factors that determine outcome DESIGN: Retrospective, analytical SETTING: Pediatric Nephrology Clinic at referral center in North India PARTICIPANTS/PATIENTS: All patients with SSNS evaluated between 1990 and 2005 INTERVENTION: None MAIN OUTCOME MEASURES: Disease course, in patients with at least 1-yr follow up, was categorized as none or infrequent relapses (IFR), frequent relapses or steroid dependence (FR), and late resistance. Details on complications and therapy with alternative agents were recorded. RESULTS: Records of 2603 patients (74.8% boys) were reviewed. The mean age at onset of illness and at evaluation was 49.7±34.6 and 67.5±37.9 months respectively. The disease course at 1-yr (n=1071) was categorized as IFR in 37.4%, FR in 56.8% and late resistance in 5.9%. During follow up, 224 patients had 249 episodes of serious infections. Alternative medications for frequent relapses (n=501; 46.8%) were chiefly cyclophosphamide and levamisole. Compared to IFR, patients with FR were younger (54.9±36.0 vs. 43.3±31.4 months), fewer had received adequate (=8 weeks) initial treatment (86.8% vs. 81.7%) and had shorter initial remission (7.5±8.6 vs. 3.1±4.8 months) (all P<0.001). At follow up of 56.0±42.6 months, 77.3% patients were in remission or had IFR, and 17.3% had FR. CONCLUSIONS: A high proportion of patients with SSNS show frequent relapses, risk factors for which were an early age at onset, inadequate initial therapy and an early relapse.
Authors: Nafsika Afentou; Emma Frew; Samir Mehta; Natalie J Ives; Rebecca L Woolley; Elizabeth A Brettell; Adam R Khan; David V Milford; Detlef Bockenhauer; Moin A Saleem; Angela S Hall; Ania Koziell; Heather Maxwell; Shivaram Hegde; Eric Finlay; Rodney D Gilbert; Caroline Jones; Karl McKeever; Wendy Cook; Nicholas J A Webb; Martin T Christian Journal: Pharmacoecon Open Date: 2022-06-22
Authors: Susan Samuel; Shannon Scott; Catherine Morgan; Allison Dart; Cherry Mammen; Rulan Parekh; Alberto Nettel-Aguirre; Allison Eddy; Rachel Flynn; Maury Pinsk; Andrew Wade; Steven Arora; Geneviève Benoit; Martin Bitzan; Robin Erickson; Janusz Feber; Guido Filler; Pavel Geier; Colette Girardin; Silviu Grisaru; James Tee; Kyle Kemp; Michael Zappitelli Journal: Can J Kidney Health Dis Date: 2014-07-22
Authors: Andrea Pasini; Cristina Bertulli; Luca Casadio; Ciro Corrado; Alberto Edefonti; GianMarco Ghiggeri; Luciana Ghio; Mario Giordano; Claudio La Scola; Cristina Malaventura; Silvio Maringhini; Antonio P Mastrangelo; Marco Materassi; Francesca Mencarelli; Giovanni Messina; Elena Monti; William Morello; Giuseppe Puccio; Paola Romagnani; Giovanni Montini Journal: Front Pediatr Date: 2021-07-08 Impact factor: 3.418